Koss Olinger Consulting LLC Increases Stake in Becton, Dickinson and Company (NYSE:BDX)

Koss Olinger Consulting LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 30.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,156 shares of the medical instruments supplier’s stock after purchasing an additional 272 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Becton, Dickinson and Company were worth $279,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. WR Wealth Planners LLC raised its position in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its position in Becton, Dickinson and Company by 2.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after acquiring an additional 43 shares in the last quarter. Clear Creek Financial Management LLC lifted its holdings in Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its holdings in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BDX. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Trading Down 1.4 %

Shares of BDX opened at $240.45 on Tuesday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The stock has a market cap of $69.49 billion, a PE ratio of 52.96, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The firm’s fifty day moving average is $237.14 and its two-hundred day moving average is $235.16. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.96 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.